Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MYC | P01106 | 3/20 | 0.47 |
| ▸ | MAX | P61244 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.45 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | FOS | P01100 | 1/20 | 0.43 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28607405 | 0.88 | PTPN11 (0.51) | ALDH1A1TSHRMYCMAXRXRA | |
| SCHEMBL828886 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TSHRMYCMAXMAPT | |
| SCHEMBL27557397 | 0.84 | ALDH1A1 (0.60) | ALDH1A1TSHRMYCMAPTNR1H4 | |
| SCHEMBL4281903 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHRMAPTXDHNR1H4 | |
| SCHEMBL4856552 | 0.82 | ALDH1A1 (0.54) | ALDH1A1TSHRMAPTXDHHIF1A | |
| SCHEMBL4276431 | 0.82 | FOS (0.49) | ALDH1A1TSHRMAPTXDHNR1H4 | |
| SCHEMBL4734254 | 0.81 | ALDH1A1 (0.57) | ALDH1A1TSHRMYCMAXMAPT | |
| SCHEMBL4279121 | 0.80 | ALDH1A1 (0.47) | ALDH1A1TSHRMYCMAXMAPT | |
| SCHEMBL28663371 | 0.79 | AR (0.51) | ALDH1A1TSHRMAPTXDHHIF1A | |
| SCHEMBL6198908 | 0.79 | ALDH1A1 (0.59) | ALDH1A1TSHRMAPTRXRAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| CN-1325376-A | Novel compound and medical use thereof | TOYAMA CHEMICAL CO LTD (JP) | 2001-12-05 | — | — | CN | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | ALDH1A1 2031/4885TSHR 4233/4885MYC 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.